The PQvTAG meetings will be held in April, May and June and aim to develop and finalise the administrative and technical guidance documents for the pre-qualification of inactivated FMD vaccines.

There will also be an opportunity to discuss other elements of the implementation of PQv with the aim of creating a sustainable system that is streamlined with identifiable objective benefits to stakeholders and a positive benefit-cost ratio for manufacturers of FAST vaccines participating in the scheme.